How GLP-1 Medicines Actually Work

Every time you eat, your gut sends a chemical message to your brain. One of the molecules carrying that message is a hormone called glucagon-like peptide-1, or GLP-1. It is released within minutes of food arriving, it nudges the pancreas, it slows the stomach, and it tells the brain you have had enough. Then, within a couple of minutes, an enzyme chops it up and it is gone.

Semaglutide, liraglutide and the rest of the class do one deceptively simple thing: they imitate that natural signal and refuse to be switched off so quickly. That is the whole trick. Understanding it properly is the best defence against both the hype that surrounds these drugs and the dismissiveness that treats them as a vanity shortcut. They are neither miracle nor cosmetic. They are a long-term medical treatment for a chronic condition, and like all such treatments they work through specific, knowable biology.

The incretin system, in plain language

The phenomenon at the heart of all this has a name that predates the drugs by decades: the incretin effect. Swallow a dose of glucose and your insulin response is markedly larger than if the identical amount of glucose is dripped straight into a vein. The difference is the gut. Eating triggers the release of hormones — incretins — that prime the pancreas before the sugar even reaches the bloodstream. GLP-1 is the most important of them.

GLP-1 does several jobs at once. It stimulates the pancreas to release insulin, but cleverly only when blood glucose is actually raised, which is why these drugs rarely cause dangerous low sugars on their own. It suppresses glucagon, a hormone that pushes glucose up. It slows the rate at which the stomach empties, so a meal is released into the intestine more gradually. And it acts on appetite centres in the brain — particularly the hypothalamus — to reduce hunger and increase the sense of fullness.

For years this was interesting endocrinology with limited practical use, because natural GLP-1 vanishes within minutes. The breakthrough was chemical, not conceptual: redesign the molecule so the body's enzymes cannot dismantle it quickly. That single modification turned a fleeting gut signal into a medicine that lasts hours, or with the latest formulations, a full week.

Why appetite, not willpower, is the real target

The part that surprises people is how much of the effect is in the brain. It is tempting to imagine these drugs work mechanically — a stomach held shut, food physically blocked. Slowed gastric emptying is real and contributes, especially to the early feeling of fullness and to some of the side effects. But the larger and more durable effect is a genuine reduction in appetite and in what researchers rather drily call food noise: the persistent background pull towards eating that many people with obesity describe and that thinner people often struggle to imagine.

This matters because it reframes what the medicine is doing. It is not overriding a weak will. It is altering a biological appetite signal that, in many people, has been set too high by a combination of genetics, physiology and a food environment engineered to be hard to resist. People on these drugs frequently report that the constant negotiation with food simply quietens. That is the appetite system being turned down, and it is the clearest evidence that obesity is driven by regulated biology rather than character.

What the trials actually showed

The reason this class reorganised obesity medicine is that the trial results were not incremental. In the STEP programme, the studies of semaglutide for weight management, participants on the higher dose alongside lifestyle support lost on average around 15% of their body weight over roughly a year — figures that older weight-loss drugs had never approached and that previously belonged only to surgery. For tirzepatide, the dual-incretin medicine studied in the SURMOUNT-1 trial, average weight loss climbed higher still. The SURPASS programme, looking at the same drug in type 2 diabetes, showed substantial improvements in blood glucose alongside weight reduction.

A few caveats keep these numbers honest. They are averages: some people lose a great deal, a minority lose little, and individual results vary widely. They were achieved with structured support — diet and activity advice, regular contact — not the drug alone. And they reflect highly selected trial populations followed under close supervision, which is not identical to ordinary life. Even with all those qualifications, the effect sizes were large enough to change guidelines and, arguably, the cultural conversation about obesity.

GLP-1 alone versus the dual-incretin approach

There are now two broad designs on the market. The first generation — semaglutide and liraglutide — targets the GLP-1 receptor alone. The newer approach, tirzepatide, adds a second incretin called GIP (glucose-dependent insulinotropic polypeptide), acting on both receptors at once. The theory is that the two gut hormones complement each other, and the trial weight-loss figures for the dual agent have tended to run higher.

It would be a mistake, though, to read this as a simple league table where newer always means better for everyone. The drugs differ in dosing, tolerability, licensed indications, cost and availability, and the right choice for a given person depends on their full medical picture — other conditions, other medicines, how they tolerate the dose escalation, and what they are actually being treated for. That is a clinical judgement, not a shopping decision, and it belongs with a prescriber who knows the person's history.

Licensed medicine versus the grey market

Because demand has outstripped supply and the headlines have been relentless, a parallel market has grown up around these drugs: unlicensed products sold online, vials of powder marketed to be mixed at home, and outright counterfeit pens. The MHRA, the UK medicines regulator, has issued repeated warnings about fake semaglutide pens and unregulated sources, including seizures of falsified products that contained the wrong substance entirely, or an unknown dose, or nothing useful at all.

This is not a minor footnote. A licensed medicine comes with a known molecule, a known dose, a regulated manufacturing chain, a prescriber who has assessed suitability, and a pharmacovigilance system that tracks harms. A vial bought from an unverified website comes with none of these. The appeal is understandable — cost, convenience, embarrassment about asking — but the risk is real and occasionally serious. These are prescription medicines for good reasons, and the safe route runs through a regulated prescriber and a registered pharmacy.

Practical takeaways

• GLP-1 medicines copy a natural gut hormone that you already release when you eat, and slow the body's ability to break it down.
• Their main effect is on appetite and the brain's hunger signalling, not simply on physically restricting the stomach.
• Trial results (STEP, SURMOUNT-1, SURPASS) showed weight loss far beyond older drugs, but as averages, achieved with structured support, in selected populations.
• Dual-incretin medicines add a second hormone target; "newer" does not automatically mean "right for any given person".
• Unlicensed online products and counterfeit pens are a genuine safety risk — a regulated prescriber and registered pharmacy are the safe route.

What this doesn't mean

It does not mean these medicines are a cosmetic shortcut or a substitute for the rest of health. They are treatments for a chronic medical condition, used under supervision, and they work best as part of a wider plan rather than instead of one. Nor does understanding the mechanism tell you whether any particular person should take one — that is an entirely separate clinical question.

When to seek medical advice

If you are considering treatment for obesity or weight-related health problems, that conversation belongs with a qualified clinician who can assess your full history, not with a website selling pens. If you are already taking a GLP-1 medicine and develop severe or persistent abdominal pain, repeated vomiting, signs of dehydration, or any symptom that worries you, seek medical advice promptly.

A closing thought

The most striking thing about these drugs is how unexotic their core idea is. They do not invent a new biology; they borrow an old one, sustaining a signal the body sends every time it is fed. That a hormone you make in your own gut, copied and made to last, can shift outcomes that willpower never could is perhaps the clearest argument that obesity was never mainly a question of willpower in the first place.

Further reading and sources

• NICE TA875 and TA1026 — technology appraisals on semaglutide and tirzepatide for weight management
• MHRA — warnings on falsified GLP-1 pens and unregulated online sources
• STEP programme — randomised trials of semaglutide for weight management
• SURMOUNT-1 and the SURPASS programme — tirzepatide trials in obesity and type 2 diabetes
• Endocrine Society — clinical guidance on the management of obesity

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.